Recombinant Human Insulin-Like Growth Factor I: Effects in Normal Subjects and Implications for Use in Patients
Two major forms of insulin-like growth factors (IGF-I and IGF-II) and their specific binding proteins have been detected in body fluids, including serum, cerebrospinal fluid, breast milk, lymph, and saliva. Extracts of almost any tissue reveal the presence of IGFs. Many cells in culture secret IGFs and various forms of their carrier proteins into the medium (1–3).
KeywordsGrowth Hormone Growth Hormone Secretion Specific Binding Protein Dawn Phenomenon Snell Dwarf Mouse
Unable to display preview. Download preview PDF.
- 5.Hardouin S, Gourmelen M, Noguiez P, Seurin D, Roghani M, LeBouc Y, Povoa G, Merimee TJ, Hossenlopp P, Binoux M. Molecular Forms of Serum Insulin-Like Growth Factor (IGF)-Binding Proteins in Man: Relationships with Growth Hormone and IGFs and Physiological Significance. J Clin Endocrin Metabol 65:1291– 1301, 1989.CrossRefGoogle Scholar
- 9.Zapf J, Schmid C., Guler HP, Waldvogel M, Hauri C., Futo E, Hossenlopp P, Binoux M, Froesch ER. Regulation of Binding Proteins for Insulin-Like Growth Factors (IGF) in Man: Increased Expression of IGF Binding Protein-2 During IGF-I Treatment of Healthy Adults and in Patients with Extrapancreatic Tumor Hypoglycemia. J Clin Invest; 86:952–962, 1990.PubMedCrossRefGoogle Scholar
- 16.Van Schravendijk C, Heylen L, Van Den Brande JL, Pipeleers D. Effects of Insulin and IGF-I on the Secretory Activity of Pancreatic B-Cells. Diabetologia 32:551A, 1989.Google Scholar
- 18.Keller S, Schmid Ch, Zapf J, Froesch ER. Inhibition of insulin degradation by insulin-like growth factors I and II in human hepatoma (HepG2) cells. Acta Endocrin 121:279–285, 1989.Google Scholar
- 20.Jacob R, Bowen L, Fryburg D, Fagin K, Tamborlane W, Shulman GI. Increased Metabolic Response to IGF-I in Insulin Resistant Diabetic BB Rats. Ann. Meeting Amer. Diab Assn., Detroit 1989, Abstract #261.Google Scholar
- 27.Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, Bolli GB. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type I (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 33:52–59, 1990.PubMedCrossRefGoogle Scholar